Sign in
Virtual Congress
About us
Resources
BeiGeneius Resources
BeiGeneius Webinars
Pipeline
Congress calendar
Services
memoinOncology
beigenemedical.com
About us
ASPEN
BeiGene
EHA
ESMO
NSCLC
PD-1
Waldenström
ALPINE: Zanubrutinib vs ibrutinib in R/R CLL/SLL
Back
View
PDF
2
06/2021
View
Rating
Rate this resource
Select a rating
Excellent
Very Good
Average
Poor
Terrible
Related resources
EHA25 - Virtual Satellite Symposium
Tislelizumab (BGB-A317) for relapsed/refractory peripheral T-cell lymphomas: safety and efficacy results from a phase 2 study
EP789: Zanubrutinib in R/R MCL: Long-term efficacy and safety data
Back
×
This function is only available for registered users.
Your Benefits of registering:
- Use all service functions directly
- Newsletter registration
- Personal library
Recent developments
Stay up to date on developments in cancer treatment and subscribe to our newsletter.
Subscribe
Welcome to the BeiGene EU Medical Information Website
This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit
beigene.com
for more information.
I am a Healthcare Professional from:
I am not a healthcare professional
×
You are now leaving the website of BeiGene EU.
You have selected a reference (hyperlink) that leads to an external website. You are leaving the internet pages of BeiGene EU. BeiGene EU is not responsible for the content of websites that can be reached by activating a hyperlink.
Do you really want to leave the website of BeiGene EU?
×
You are now leaving the italian website of BeiGene EU.
You are now leaving the italian website of BeiGene EU.
Please check your webbrowser
We noticed that your webrowser doesn't meet the requirements, please upgrade!
OK
